Navigation Links
Silence Therapeutics Appoints New Vice President of Research
Date:5/5/2010

LONDON, May 5 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces the promotion of Jorg Kaufmann, Ph.D., to the position of vice president of research.  In this new position, Dr. Kaufmann, who previously served as senior director, technologies at Silence, will play a key role in overseeing the Company's broad range of RNA interference (RNAi) research activities, including those focused on advancing Silence's novel small interfering RNA (siRNA) delivery technologies.  Dr. Kaufmann will continue to be based at Silence's Berlin research center, where the Company recently announced it is consolidating all research activities related to its novel RNAi therapeutic platforms.

Dr. Kaufmann possesses more than 13 years of biotechnology industry experience in both the United States and Europe.  Since joining Silence in 2000, he has served as both senior and associate director, technologies at the Company's Berlin location.  Prior to joining Silence, Dr. Kaufmann was a senior scientist at Chiron Corporation, where he was responsible for leading one of the company's molecular biology research groups focused on breast cancer.  From 1996-1997 he served as a group leader at the Institute of Tumour Biology (IMT) in Marburg, Germany.  Dr. Kaufmann was a postdoctoral fellow at the Howard Hughes Medical Institute, University of California, Los Angeles and received his Ph.D. in molecular biology from the Philipps University Marburg.

"In his time at Silence Dr. Kaufmann has proven himself a valued member of our research team, playing a significant role in a
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
2. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
3. Silence Therapeutics Receives Allowance from United States Patent and Trademark Office for its Core RNAi Patent
4. Silence Therapeutics Patent Update
5. Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
6. Organizational Changes at Silence Therapeutics
7. Silence Therapeutics Announces Successful Opposition of Glover Patent
8. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
9. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
10. Talecris Biotherapeutics to Report First Quarter 2010 Financial Results
11. Live Webinar: Paperless QC Micro Implemented by Talecris Biotherapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... (PRWEB) August 28, 2014 Earlier this ... University in partnership with the U.S. Air Force ... biofuel. The results indicated that this type of fuel ... feedstock and will be important to America’s Eco friendly ... now has a mandate to become independent of foreign ...
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce that ... PTI Inspection Systems that will enable it to ... leak testing method development and validation programs using the ... part of this agreement, Whitehouse Labs has taken delivery ... developed and manufactured by PTI. The HVLD (high ...
(Date:8/27/2014)... Rhythm, a biopharmaceutical company developing peptide therapeutics that address ... disorders, announced today that it has filed a registration ... Exchange Commission (SEC) relating to the proposed initial public ... of shares to be offered and the price range ... Citigroup and Cowen and Company will act as ...
(Date:8/27/2014)... 27, 2014   MSC , a healthcare performance ... announced the appointment of Mary Beth Loesch ... years of experience preparing companies for rapid growth and ... Vice President of Corporate Development and Healthcare. In that ... , as well as corporate strategy and marketing. Previously, ...
Breaking Biology Technology:Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 2Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 3Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 4Can Small Farmers and a New Seed Based Biofuel “Green” the World? Major Universities and Even the U.S. Air Force Seem to Think So 5Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Rhythm Files Registration Statement for Proposed Initial Public Offering 2MSC names Mary Beth Loesch President and CEO 2
... Oct. 22 Insmed Inc. (Nasdaq:,INSM), a developer of ... of the recently disclosed temporary suspension,of NASDAQ,s minimum bid ... that the Company now has until March 20, 2009 ... evidence a closing bid price of $1.00 or more ...
... Oct. 22 MiddleBrook,Pharmaceuticals, Inc. (Nasdaq: ... and commercializing novel anti-infective products, today,announced that ... to lead its field force hiring effort ... tablets, 775mg) launch. The,launch is targeted for ...
... COX) today reported financial results for the nine,months ended September 30, ... - Positive top-line results from the 302 study for naproxcinod. ... at week-13 (p naproxcinod 750 mg bid comfortably ... naproxen 500 mg bid at week-13 and 26. Blood ...
Cached Biology Technology:NASDAQ's Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmed's Compliance Date to March 20, 2009 2MiddleBrook Hires TalenTactics to Recruit National Field Force 2MiddleBrook Hires TalenTactics to Recruit National Field Force 3NicOx Reports Results for the First Three Quarters of 2008 2NicOx Reports Results for the First Three Quarters of 2008 3NicOx Reports Results for the First Three Quarters of 2008 4NicOx Reports Results for the First Three Quarters of 2008 5NicOx Reports Results for the First Three Quarters of 2008 6NicOx Reports Results for the First Three Quarters of 2008 7NicOx Reports Results for the First Three Quarters of 2008 8NicOx Reports Results for the First Three Quarters of 2008 9NicOx Reports Results for the First Three Quarters of 2008 10
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
(Date:8/29/2014)... Bend them, stretch them, twist them, fold them: modern ... extraordinary technological potential, whether as artificial skin or electronic ... use remains a challenge but a new way of ... could be a game-changer. , Previous success in ... on the use of precious gold and silver nanowires. ...
(Date:8/28/2014)... of bacterial culprits that may drive inflammatory bowel diseases ... patients, own intestinal immune responses as a guide. , ... Cell . , Trillions of bacteria exist within ... in the development and progression of IBD. Yet it,s ... affect a person,s susceptibility to IBD and its potential ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Copper shines as flexible conductor 2Yale study identifies possible bacterial drivers of IBD 2
... pleased to announce the publication of an up-to-date, concise ... patients. , Small Animal Regional Anesthesia and Analgesia provides ... and is organized logically by body system. , ... into one resource, Small Animal Regional Anesthesia and Analgesia ...
... Small Animal Soft Tissue Surgery offers the state-of-the-art, ... and syndromes in small animal patients, with detailed, ... surgical techniques in a well-illustrated, easy-to-follow format, the ... diseases and syndromes, with video clips and slideshows ...
... . First detected in the United States a ... at least 39 states, is wreaking havoc in homes and gardens, ... and row crops. It,s no wonder the U.S. Department of Agriculture ... But help may be on the way: USDA scientists ...
Cached Biology News:Combating USDA's top-ranked invasive insect 2
... siTrio siRNA --- a cocktail of ... gene of interestis our most popular product. ... than 75% knockdown of your target gene ... siRNA for transfection and confirmation of optimal ...
... #27295 has improved stability and convenience from the ... only has overcome this problem but also produced ... changed the formulation of HRP conjugated antibody from ... this change, the stability of the conjugate has ...
Mouse monoclonal [1.F.1] to Yersinia pestis F1 antigen ( Abpromise for all tested applications). Antigen: Purified F1 antigen of Y. pestis vaccine strain EB....
Sheep polyclonal to Salmonella Shoreditch ( Abpromise for all tested applications). Antigen: Native Salmonella shoreditch (Group D2)....
Biology Products: